Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | Review of BTK inhibition in MS

Shane Arsenault, MD, Memorial University of Newfoundland, St. John’s, Canada, reviews the current understanding and ongoing clinical trials of Bruton Tyrosine Kinase (BTK) inhibitors that are emerging as potential medical treatments for the varying subtypes of multiple sclerosis (MS). Currently, several BTK inhibitors are being investigated, including tolebrutinib, evobrutinib, orelabrutinib, and fenebrutinib. Evobrotinub and tolebrutinib are farthest along in clinical development for the treatment of MS. In Phase II clinical trials in relapsing MS, both evobrutinib and tolebrutinib strongly reduced new gadolinium-enhancing lesions, and safety data have been reassuring. Overall, BTK inhibitors have shown positive results in reducing primary and secondary endpoints in various clinical trials. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.